Related Experiment Video
Updated: May 14, 2026
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
Identification of a synthetic muramyl peptide derivative with enhanced Nod2 stimulatory capacity
Stephen J Rubino1, Joao G Magalhaes, Dana Philpott
11Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Abstract:
Muramyl peptides (MPs) represent the building blocks of bacterial peptidoglycan, a critical component of bacterial cell walls. MPs are well characterized for their immunomodulatory properties, and numerous studies have delineated the role of MPs or synthetic MP analogs in host defense, adjuvanticity and inflammation. More recently, Nod1 and Nod2 have been identified as the host sensors for specific MPs, and, in particular, Nod2 was shown to detect muramyl dipeptide (MDP), a MP found in both Gram-positive and Gram-negative bacterial cell walls. Because mutations in Nod2 are associated with the etiology of Crohn's disease, there is a need to identify synthetic MP analogs that could potentiate Nod2-dependent immunity. Here, we analyzed the Nod2-activating property of 36 MP analogs that had been tested previously for their adjuvanticity and anti-infectious activity. Using a luciferase-based screen, we demonstrate that addition of a methyl group to the second amino acid of MDP generates a MDP derivative with enhanced Nod2-activating capacity. We further validated these results in murine macrophages, human dendritic cells and in vivo. These results offer a basis for the rational development of synthetic MPs that could be used in the treatment of inflammatory disorders that have been associated with Nod2 dysfunction, such as Crohn's disease.
Insights
Researchers identified a novel synthetic muramyl dipeptide (MDP) analog that enhances Nod2-dependent immunity. This finding offers potential for developing new treatments for inflammatory disorders like Crohn
Area of Science:
- Immunology
- Microbiology
- Medicinal Chemistry
Background:
- Muramyl peptides (MPs) are bacterial peptidoglycan components with known immunomodulatory effects.
- Nod1 and Nod2 are host sensors for MPs, with Nod2 detecting muramyl dipeptide (MDP).
- Nod2 dysfunction is linked to Crohn's disease, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify synthetic muramyl peptide (MP) analogs that enhance Nod2-dependent immunity.
- To explore potential therapeutic agents for Nod2-related inflammatory disorders, including Crohn's disease.
Main Methods:
- Screened 36 MP analogs for Nod2-activating properties using a luciferase-based assay.
- Validated the most promising analog in murine macrophages, human dendritic cells, and in vivo.
- Analyzed the structure-activity relationship of MDP derivatives.
Main Results:
- A novel MDP derivative with an added methyl group demonstrated enhanced Nod2-activating capacity.
- This enhanced activity was confirmed across cellular and in vivo models.
- The study identified a specific structural modification that potentiates Nod2 signaling.
Conclusions:
- The identified MDP analog provides a basis for developing synthetic MPs to modulate Nod2-dependent immunity.
- These findings support the rational design of therapeutics for inflammatory conditions associated with Nod2 dysfunction.
- This research paves the way for novel treatments for Crohn's disease and other related disorders.
